Covid-19 Messaging to Underserved Communities - 2nd Experiment

July 24, 2021 updated by: Esther Duflo, National Bureau of Economic Research, Inc.
The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19. The sample will include African American and white adult Americans and oversample those with less than a college degree.

Study Overview

Detailed Description

Recent data have shown that covid19 is disproportionately infecting and killing African Americans and Latinx people in the United States. Moreover, since our last experiment, the killing of George Floyd by Minnesota police has raised awareness of structural racism in the United States.

The aim of the study is to build off results from our first experiment (NCT04371419) , and test whether messages that acknowledge racial injustice on behalf of institutions affect the retention of knowledge and movement of beliefs and behavior with respect to Covid-19. The investigators will also test the effect of concordance of providers and whether highlighting the unequal burden of the disease has additional effects on knowledge, beliefs and behavior regarding covid-19.The sample will include African American and white adult Americans and oversample those with less than a college degree.

Study Type

Interventional

Enrollment (Actual)

20460

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Cambridge, Massachusetts, United States, 02138
        • JPAL North America

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adults who self-identify as African American or white.
  • an oversample of individuals with less than a college education

Exclusion Criteria:

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: AMA RI - B- B - R
Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
Experimental: AMA RI - B - B - N
Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Experimental: AMA RI - W - W - R
Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Experimental: AMA RI - W - W - N
Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Experimental: AMA DP - B- B - R
Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Experimental: AMA DP - B- B - N
Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Experimental: AMA DP - W- W - R
Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
Investigators will include information on race-specific covid-19 cases and deaths in one variation in the messaging. In this arm, participants receive disproportionate race-specific Covid-19 facts
Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Experimental: AMA DP - W- W - N
Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
In this arm, the disproportionate burden of Covid-19 on communities of color will not be highlighted
Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Placebo Comparator: Control: AMA RI - B - B

Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.

Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.

African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA

Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Videos not related to covid-19 will be shown
Placebo Comparator: Control: AMA RI - W - W

Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.

Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.

White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA

Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.
Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Videos not related to covid-19 will be shown
Placebo Comparator: Control: AMA DP - B - B

Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.

African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA

AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing

Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA
Investigators will vary the sender of the informational covid-19 videos. In this arm, participants receive a African American sender in informational videos.
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Videos not related to covid-19 will be shown
Placebo Comparator: Control: AMA DP - W - W

Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.

White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA

AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing

Investigators will also vary the messenger of the acknowledgement sender. In this arm, participants receive a white sender in the acknowledgement
Investigators will vary the messenger of the informational covid-19 videos. In this arm, participants receive white sender in the informational video
Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing
Videos not related to covid-19 will be shown

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence Rate for Knowledge Gaps: Control vs. Any Intervention
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10.
The outcome was measured immediately following the intervention in the baseline survey.
Incidence Rate for Knowledge Gaps: Control vs. Any Intervention - Follow up
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. Incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10.
The outcome was measured at a follow-up within 2 weeks following the intervention
Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
Participants were offered the option of requesting additional information on COVID-19 related resources by clicking on up to five links that included more content. We measured "information seeking behavior" as the number of links for which participants expressed interest, a count variable between 0 (lowest information seeking behavior) and 5 (greatest information seeking behavior). Incidence rate for interest in links is the count of links demanded divided by the maximum possible count: 5.
The outcome was measured immediately following the intervention in the baseline survey.
Incidence Rate - Safety Gap Score: Control vs. Any Intervention
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention.
Participants were asked about how often they engaged in four behaviors of interest: if they wore a mask indoors/outdoors; if they washed their hands; if they followed social distancing guidelines. The safety gap index takes values of 0 (if a participant reported that they always practiced the four behaviors of interest) up to 4 (none). Incidence rate for safety gaps is the count of safety gaps divided by the maximum possible count: 4.
The outcome was measured at a follow-up within 2 weeks following the intervention.
Willingness to Pay (WTP) for Masks: Control vs. Any Intervention
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
WTP: the participants will be asked to choose between two masks vs an unrestricted gift card. They will be asked what amount of gift card would make them just as happy to receive two mask versus the gift card.
The outcome was measured immediately following the intervention in the baseline survey.
Incidence Rate Ratio (IRR) - Knowledge Gap
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
The outcome was measured immediately following the intervention in the baseline survey.
Incidence Rate Ratio (IRR) - Knowledge Gap - Follow up
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention
Participants were asked to identify ways to prevent COVID-19 spread and identify four common symptoms. The incidence rate for knowledge gaps is the count of knowledge gaps divided by the maximum possible count: 10. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
The outcome was measured at a follow-up within 2 weeks following the intervention
Incidence Rate Ratio (IRR) - Information-seeking Behavior
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
Participants were offered the option of requesting additional information on COVID-19 related resources by clicking on up to 5 links that included more content. We measured "information seeking behavior" as the number of links for which participants expressed interest, a count variable between 0 (lowest information seeking behavior) and 5 (greatest information seeking behavior). Incidence rate for interest in links is the count of links demanded divided by the maximum possible count: 5. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
The outcome was measured immediately following the intervention in the baseline survey.
Incidence Rate Ratio (IRR) - Safety Gap Score
Time Frame: The outcome was measured at a follow-up within 2 weeks following the intervention.
Participants were asked about how often they engaged in four behaviors of interest: if they wore a mask indoors/outdoors; if they washed their hands; if they followed social distancing guidelines. The safety gap index takes values of 0 (if a participant reported that they always practiced the four behaviors of interest) up to 4 (none). Incidence rate for safety gaps is the count of safety gaps divided by the maximum possible count: 4. The incidence rate ratio compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single negative binomial regression.
The outcome was measured at a follow-up within 2 weeks following the intervention.
OLS Regression Coefficients - Willingness to Pay (WTP) for Masks
Time Frame: The outcome was measured immediately following the intervention in the baseline survey.
WTP: the participants will be asked to choose between two masks vs an unrestricted gift card. They will be asked what amount of gift card would make them just as happy to receive two mask versus the gift card. The regression coefficients compares the incidence rate of participants in Arm A vs. Arm B within the intervention group (i.e. those who received covid-19-related videos), within in the control group (i.e. those who saw placebo videos), or across the intervention and control group. Arms A and B are described in each Arm/Group Title. The overall number of participants analyzed is all equal across 6 arms/groups because the outcome measure data presented below came from a single ordinary least squares (OLS) regression for WTP masks).
The outcome was measured immediately following the intervention in the baseline survey.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 7, 2020

Primary Completion (Actual)

September 6, 2020

Study Completion (Actual)

September 6, 2020

Study Registration Dates

First Submitted

August 2, 2020

First Submitted That Met QC Criteria

August 4, 2020

First Posted (Actual)

August 6, 2020

Study Record Updates

Last Update Posted (Actual)

July 27, 2021

Last Update Submitted That Met QC Criteria

July 24, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

3
Subscribe